This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chromadex, The Potential "Game Changer" In Patient Dependency Of The Multi-Billion Dollar Pharmaceutical Industry

Despite high levels of productivity with lowering blood pressure, taking beta blockers can decline good cholesterol levels, which can then increase chances of a heart attack. In rare cases, other side effects include memory loss, diarrhea, abdominal pain, and sore throat. Riche believes that the blood pressure findings of pterostilbene are promising because the compound fails to present any side effects. However, he thinks more research can answer further questions about the potential of pterostilbene .

"Ultimately I feel it is a promising product in cardiometabolics, but it needs further evaluation and further looking into," said Riche.

Chromadex has high hopes for other product brands expected to launch within the next year. These brands include the anthocyanin-based ProC3G and the niacin-rooted Nicotinamide Riboside. Although natural, heavy users of niacin can suffer from flushing, a side effect which causes hot itch skin irritation. Nicotinamide Riboside is a metabolite of niacin which according to Jaksch, negates the side effect.

"The flush effect is a big deal because if you take a reasonable dosage, it will make you feel uncomfortable. There is no flush effect with this metabolite that we have. Not only does it fix that, but it is also a more powerful version of the compound that should be more effective than niacin," said Jaksch.

While some will question whether it is possible for predominantly organic products to have more potency than prescription drugs without the side effects, Jaksch is set on using science to back the claims of his products.

"When most people talk about dietary supplements or vitamins sometimes, there's usually a high level of skepticism around these types of products. The general perception is that there isn't much science underlying each of these things. Because of this, we are trying to build a body of evidence which is much larger than expected.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs